Pneumonia Vaccine Market Growing at a CAGR of 5.6% | 2023-29

1
(No Transcript)
2
Market Overview
The global pneumonia vaccine market size was
valued at USD 8.4 billion in 2022 and is poised
to grow at a significant CAGR of 5.6 during the
forecast period 2023-29. The pneumonia vaccine
market research report also provides
opportunities for business owners to exploit
through the use of relevant approaches. The
studys prospects assist stakeholders and report
purchasers in properly planning their investments
and augmenting their profits. The report
provides a quantitative analysis of the market
segments, trends, estimations, and dynamics of
the pneumonia vaccine market analysis from 2023
to 2029 to identify the prevailing market
opportunities. In addition, the report discusses
the implications of COVID-19, including the
industry's initial response and strategies for
ensuring business continuity in the coming
years. View Detailed Report Description
3
Market Segments

• The pneumonia vaccine market has been fragmented
  based on
• By Product Type Prevnar 13, Synflorix, and
  Pneumovax 23.
• By Dosage Single Dose Vial and Pre-filled
  Syringe.
• By End User Child, Adult and Geriatric.
• By Vaccine Type Pneumococcal Conjugate Vaccine,
  and Pneumococcal Polysaccharide Vaccine
• Request Sample Report

4
Key Players

• Some of the major key players in the pneumonia
  vaccine market are
• GlaxoSmithKline plc
• Pfizer Inc
• CSL Ltd
• Merck Co., Inc.,
• Serum Institute of India Pvt. Ltd
• Sanofi Pasteur Inc.
• Request Sample Report

5
Europe Office Precision Business Insights, Kemp
House, 152 160 City Road, London EC1V
2NX Asia-Pacific Office Precision Business
Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB
Colony, Hyderabad 500072 Email sales_at_precisionb
usinessinsights.com Toll-Free 1-866-598-1553